Full metadata record

DC Field Value Language
dc.contributor.authorEl-Gamal, Mohammed, I-
dc.contributor.authorAl-Ameen, Shahad K.-
dc.contributor.authorAl-Koumi, Dania M.-
dc.contributor.authorHamad, Mawadda G.-
dc.contributor.authorJalal, Nouran A.-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-19T22:04:57Z-
dc.date.available2024-01-19T22:04:57Z-
dc.date.created2022-01-10-
dc.date.issued2018-07-12-
dc.identifier.issn0022-2623-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/121152-
dc.description.abstractColony stimulation factor-1 receptor (CSF-1R), which is also known as FMS kinase, plays an important role in initiating inflammatory, cancer, and bone disorders when it is overstimulated by its ligand, CSF-1. Innate immunity, as well as macrophage differentiation and survival, are regulated by the stimulation of the CSF-1R. Another ligand, interlukin-34 (IL-34), was recently reported to activate the CSF-1R receptor in a different manner. The relationship between CSF-1R and microglia has been reviewed. Both CSF-1 antibodies and small molecule CSF-1R kinase inhibitors have now been tested in animal models and in humans. In this Perspective, we discuss the role of CSF-1 and IL-34 in producing cancer, bone disorders, and inflammation. We also review the newly discovered and improved small molecule kinase inhibitors and monoclonal antibodies that have shown potent activity toward CSF-1R, reported from 2012 until 2017.-
dc.languageEnglish-
dc.publisherAMER CHEMICAL SOC-
dc.subjectTUMOR-ASSOCIATED MACROPHAGES-
dc.subjectMONOCLONAL-ANTIBODY-
dc.subjectINFILTRATING MACROPHAGES-
dc.subjectRHEUMATOID-ARTHRITIS-
dc.subjectSPECIES-SPECIFICITY-
dc.subjectTYROSINE KINASES-
dc.subjectPOTENT CLASS-
dc.subjectC-FMS-
dc.subjectCANCER-
dc.subjectCELL-
dc.titleRecent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors-
dc.typeArticle-
dc.identifier.doi10.1021/acs.jmedchem.7b00873-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF MEDICINAL CHEMISTRY, v.61, no.13, pp.5450 - 5466-
dc.citation.titleJOURNAL OF MEDICINAL CHEMISTRY-
dc.citation.volume61-
dc.citation.number13-
dc.citation.startPage5450-
dc.citation.endPage5466-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000439006100002-
dc.identifier.scopusid2-s2.0-85046648355-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusTUMOR-ASSOCIATED MACROPHAGES-
dc.subject.keywordPlusMONOCLONAL-ANTIBODY-
dc.subject.keywordPlusINFILTRATING MACROPHAGES-
dc.subject.keywordPlusRHEUMATOID-ARTHRITIS-
dc.subject.keywordPlusSPECIES-SPECIFICITY-
dc.subject.keywordPlusTYROSINE KINASES-
dc.subject.keywordPlusPOTENT CLASS-
dc.subject.keywordPlusC-FMS-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusCELL-
dc.subject.keywordAuthorCSF-1 kinase-
dc.subject.keywordAuthorBreast Cancer-
dc.subject.keywordAuthorInterleukin-34-
Appears in Collections:
KIST Article > 2018
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE